Breast Lesion Localization Market to reach US$ 390.6 bn by 2031

According to a new research study by Global Insight Services (GIS), the breast lesion localization market is expected to grow rapidly over the next 10 years to reach a value of more than the US $390.6 million by 2031.

Breast lesion localization is a medical device used in the detection of malignant and nonmalignant tumors. It is used in the preoperative marketing of nonpalatable breast lesions. There are different types of breast lesion localization devices developed using different techniques: radiations, wires, radar, and electromagnetic. Breast lesion localization methods are used to detect the abnormalities in terms of a lump or tumor in the breasts. There are various types of breast lesion localization methods used across the globe to detect a lump or tumor in the breasts. However, the rapid increase in the number of women opting for preventive screening tests for breast cancer creates a highly conducive environment for the growth of the breast lesion localization market.

Request Sample Pages of this Research Report: https://www.globalinsightservices.com/request-sample/GIS10248/

Global Breast Lesion Localization Market: Key Drivers

The major factor boosting the growth of the market is the increasing incidence of breast cancer. Breast cancer is among the most common diseases affecting women in developed and developing countries. As per the American Cancer Society, breast cancer is the second-leading cause of cancer-related deaths in women globally. Worldwide, there has been significant growth in the number of breast cancer cases. This can majorly be attributed to changing lifestyles, the increasing use of oral contraceptives, and the rising number of women undergoing cosmetic surgeries, such as breast enhancement.

Similarly, the growing rate of the aging population is also boosting the growth of the market. With age, the risk of developing breast cancer increases. Aging increases multipotent progenitors and decreases the number of myoepithelial cells, which line the breast’s milk-producing luminal cells and serve as tumor suppressors. As per the American Cancer Society, approximately 1 out of 8 invasive breast cancers develop in women less than 45 years. Conversely, approximately 2 out of 3 invasive breast cancers develop in women aged 55 and above.

Report Findings

The wire localization segment is likely to dominate the market during the forecast period

The increasing incidence of breast cancer combined with the increasing adoption of expansion strategies by manufacturers of lesion localization products, product launches, and increasing healthcare expenditure are a major factor driving the global breast lesion localization market.

The breast biopsy segment is likely to dominate the market during the forecast period

The key factors such as increasing consumption of alcohol and a sedentary lifestyle causing obesity are boosting the growth of the market.

Competitive Landscape

The global breast lesion localization market report includes players such as Hologic, Inc. (US), Becton, Dickinson and Company (US), Merit Medical Systems (US), Leica Biosystems Nussloch GmbH (US), Argon Medical Devices (US), Laurane Medical LLC (France), Endomagnetics Ltd. (UK), Intramedical Imaging, LLC (US), Isoaid (US), Surgiceye GmbH (Germany), Ranfac Corp. (US), Mermaid Medical Group (Denmark), Izi Medical Products, LLC (US), Matek Medikal (Turkey), Tsunami Medical Srl (Italy), BPB Medica (Italy), Sirius Medical Systems B.V. (Netherlands), Molli Surgical Inc. (Canada), Sterylab S.R.L. (Italy), CP Medical (Georgia), MDL SRL (Italy), Biomedical Srl (Italy), Elucent Medical (US), Vigeo srl (Italy), and Medax Medical Devices (Italy).